ProCE Banner Activity

CheckMate 648: Nivolumab + Ipilimumab or Chemotherapy vs Chemotherapy Alone for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma

Slideset Download
Conference Coverage
In patients with advanced esophageal cancer and no previous therapy for advanced disease, nivolumab with either ipilimumab or chemotherapy significantly increased overall survival vs chemotherapy alone.

Released: June 11, 2021

Expiration: June 10, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme